Tranexamic acid Lysteda
Generic name: Tranexamic Acid (Lysteda)
Drug class:
Miscellaneous coagulation modifiers
Usage of Tranexamic acid Lysteda
Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
Lysteda is used to treat heavy menstrual bleeding. This medication will not treat premenstrual syndrome (PMS).
Tranexamic acid may also be used for purposes not listed in this medication guide.
Tranexamic acid Lysteda side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop taking Lysteda and call your doctor at once if you have a serious side effect such as:
Less serious side effects include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Tranexamic acid Lysteda
You should not take Lysteda if you are allergic to tranexamic acid, or if you have:
To make sure you can safely take Lysteda, tell your doctor if you have any of these other conditions:
It is not known whether tranexamic acid will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication.
Tranexamic acid can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.
Do not give this medication to anyone under 18 years old without your doctor's advice.
Do not share Lysteda with another person, even if they have the same symptoms you have.
Relate drugs
- Advate
- Adynovate
- Adynovate recombinant
- Afstyla
- Afstyla recombinant
- Agrylin
- Alphanate
- Alphanine SD
- Alprolix
- Alprolix (Factor ix fc fusion protein recombinant Intravenous)
- Altuviiio
- Altuviiio (Antihemophilic factor (recombinant), fc-vwf-xten fusion protein-ehtl Intravenous)
- Altuviiio (Antihemophilic factor Intravenous)
- Amicar
- Amicar (Aminocaproic acid Intravenous)
- Amicar (Aminocaproic acid Oral)
- Aminocaproic acid
- Aminocaproic acid (Intravenous)
- Aminocaproic acid (Oral)
- Anagrelide
- Anti-inhibitor coagulant complex
- Antihemophilic and von Willebrand factor complex
- Antihemophilic factor
- Antihemophilic factor (recombinant) pegylated-aucl
- Antihemophilic factor (recombinant) porcine sequence
- Antihemophilic factor (recombinant), fc-vwf-xten fusion protein-ehtl
- Antihemophilic factor (recombinant), glycopegylated-exei
- Antihemophilic factor human
- Antihemophilic factor recombinant
- Antihemophilic factor viii and von willebrand factor
- Artiss
- Artiss Duo Set
- Artiss Duploject
- Autoplex T
- Coagadex
- Coagulation factor IX
- Coagulation factor ix recombinant
- Coagulation factor ix recombinant, glycopegylated
- Coagulation factor viia
- Coagulation factor VIIa injection
- Coagulation factor viia-jncw
- Coagulation factor X
- Corifact
- Cyklokapron
- Bebulin VH
- BeneFIX
- Benefix (Coagulation factor ix recombinant Intravenous)
- Ceprotin
- Defibrotide
- Defitelio
- Eloctate
- Eloctate with Fc Fusion Protein recombinant
- Emicizumab
- Emicizumab-kxwh
- Esperoct (Antihemophilic factor (recombinant), glycopegylated-exei Intravenous)
- Esperoct (Antihemophilic factor Intravenous)
- Esperoct recombinant
- Evarrest
- Factor ix albumin fusion protein recombinant
- Factor IX complex
- Factor ix fc fusion protein recombinant
- Factor x human
- Factor XIII
- Feiba VH Immuno
- Feiba-VH
- Fibrin sealant topical
- Fibrinogen
- Fibrinogen and thrombin, human
- Fibrinogen/aprotinin and thrombin/calcium chloride
- Fostamatinib
- Fostamatinib disodium
- Helixate FS
- Helixate FS recombinant
- Hemlibra
- Hemofil-M
- Hemofil-M human
- Humate-P
- Hyate:C
- Idelvion
- Idelvion (Factor ix albumin fusion protein recombinant Intravenous)
- Ixinity
- Ixinity (Coagulation factor ix recombinant Intravenous)
- Jivi (Antihemophilic factor (recombinant) pegylated-aucl Intravenous)
- Jivi (Antihemophilic factor Intravenous)
- Jivi recombinant
- Koate DVI
- Koate-DVI human
- Kogenate FS
- Kogenate FS recombinant
- Kogenate FS with Adapter recombinant
- Kovaltry recombinant
- Lysteda
- Monoclate-P human
- Mononine
- Novoeight recombinant
- Novoseven
- NovoSeven RT
- NovoSeven RT with MixPro injection
- Nuwiq recombinant
- Obizur (Antihemophilic factor (recombinant) porcine sequence Intravenous)
- Obizur (Antihemophilic factor Intravenous)
- Pentopak
- Pentoxifylline
- Pentoxil
- Protein c, human
- Raplixa
- Rebinyn
- Rebinyn (Coagulation factor ix recombinant, glycopegylated Intravenous)
- Recombinate recombinant
- RiaSTAP
- Rixubis
- Rixubis (Coagulation factor ix recombinant Intravenous)
- Roctavian
- Tachosil
- Tavalisse
- Thrombin human, recombinant
- Tisseel
- Tisseel Duploject Kit
- Tisseel Valupak Kit
- Tranexamic acid
- Tranexamic acid (Intravenous)
- Tranexamic acid (Oral)
- Tranexamic acid Lysteda
- Trental
- Tretten
- Valoctocogene roxaparvovec-rvox
- Von Willebrand factor recombinant
- Vonvendi
- Wilate
- Xyntha
How to use Tranexamic acid Lysteda
Usual Adult Dose for Bleeding:
Initial dose: 10 mg/kg intravenously, immediately before dental extraction Maintenance dose: 10 mg/kg intravenously three to four times dailyDuration of therapy: 2 to 8 daysComments: Infuse no more than 1 mL/minute to avoid hypotension.Use: Short-term use in patients with hemophilia to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following a tooth extraction.
Usual Adult Dose for Menstrual Disorders:
Dose: 1300 mg (two 650 mg tablets) orally three times a day (3900 mg/day) during monthly menstruationDuration: Maximum of 5 daysUse: For the treatment of cyclic heavy menstrual bleeding
Usual Pediatric Dose for Bleeding:
Initial dose: 10 mg/kg intravenously, immediately before dental extraction Maintenance dose: 10 mg/kg intravenously three to four times dailyDuration of therapy: 2 to 8 daysComments: -The limited data suggest that dosing instructions for adults can be used for pediatric patients needing therapy for tooth extractions. -Infuse no more than 1 mL/minute to avoid hypotension.Use: Short-term use in patients with hemophilia to reduce or prevent hemorrhage and reduce the need for replacement therapy during tooth extractions.
Usual Pediatric Dose for Menstrual Disorders:
Post menarchal females: Dose: 1300 mg (two 650 mg tablets) orally three times a day (3900 mg/day) during monthly menstruationDuration: Maximum of 5 days Use: For the treatment of cyclic heavy menstrual bleeding in post-menarchal females
Warnings
You should not use this medication if you are allergic to tranexamic acid, if you have problems with the blood vessels in your eyes, or if you have ever had a stroke, blood clot, or bleeding in your brain.
Before using tranexamic acid, tell your doctor if you have kidney disease, leukemia, a history of endometriosis, or if your menstrual cycles are less than 21 days apart or longer than 35 days apart.
Do not start taking Lysteda until your period has started. Do not take it for longer than 5 days in a row. Talk with your doctor if your symptoms do not improve after 2 cycles of treatment.
Do not take more than 6 tablets in one 24-hour period.
Use a barrier form of birth control (such as a condom or diaphragm with spermicide). Hormonal contraception (such as birth control pills, injections, implants, skin patches, and vaginal rings) may increase your risk of stroke, blood clot, or heart attack if they are used at the same time as Lysteda.
Do not share Lysteda with another person, even if they have the same symptoms you have.
What other drugs will affect Tranexamic acid Lysteda
Tell your doctor about all other medicines you use, especially:
This list is not complete and other drugs may interact with Lysteda. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions